Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin prophylaxis for venous thromboembolism in first-line metastatic colorectal cancer
2023-508860-31-00Phase 3Completed
- Sponsor
- Grupo Gallego de Investigación en Tumores Digestivos
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of tinzaparin in venous thromboembolism (VTE), sponsored by Grupo Gallego de Investigación en Tumores Digestivos. Primary endpoint: Primary efficacy endpoint. Started Feb 2023; status: completed.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2023-508860-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508860-31-00.